Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cacaito who wrote (243)	1/29/1998 10:49:00 PM
From: NeuroInvestment	Read Replies (3) of 1494

It was in fact a p value of .10; i.e. a 10% statistical likelihood that the trends towards efficacy noted were due to chance, not drug action. I am generally sympathetic to more liberal statistics; the use of .05 as the criterion of 'significance' is arbitrary ('the tyranny of .05)....and there have been suggestions (regarding Myotrophin) that .10 is a reasonable criterion in disorders where there is a lack of effective treatment (a suggestion the FDA has rejected). With the small sample size, this effect may be meaningful. Having said that, I think it was a PR mistake for the Company to fudge on this...if they wanted to make a case for an expanded definition of 'significance', they should have said so. However, in the long run, the only arbiters that will matter on this trial are the pharmaceutical companies Paul Freiman is trying to cut a deal with by the end of business tomorrow....and they understand .05, .10, and the limitations of each. NeuroInvestment

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next